CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis

Yo-Han Cho, So Young Yoon, Soo-Nyung Kim

Cancer Research and Treatment. 2017;49(1):255-262. Published online 2016 May 18 DOI: https://doi.org/10.4143/crt.2015.452

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis

Yo-Han Cho, So Young Yoon, Soo-Nyung Kim

Cancer Research and Treatment. 2017;49(1):255-262

Link1

Link2 Link3

6578 A randomized phase II study of irinotecan monotherapy versus irinotecan plus 5-fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer

Y. Park, S. Sym, J. Park, E. Cho, D. Shin, J. Lee

European Journal of Cancer Supplements. 2009;7(2):383-384

Link1 Link2

Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

Kazuhiro Nishikawa, Wasaburo Koizumi, Akira Tsuburaya, Takeharu Yamanaka, Satoshi Morita, Kazumasa Fujitani, Yusuke Akamaru, Ken Shimada, Hisashi Hosaka, Norisuke Nakayama, Toshimasa Tsujinaka, Junichi Sakamoto

Gastric Cancer. 2019;23(1):160-167

Link1

Link2 Link3

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

Daisuke Takahari, Yasuhiro Shimada, Shigeyuki Takeshita, Hitoshi Nishitani, Atsuo Takashima, Natsuko Okita, Yoshinori Hirashima, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Kuniaki Shirao

Gastric Cancer. 2010;13(3):186-190

Link1

Link2 Link3

Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

K. Nishikawa, W. Koizumi, A. Tsuburaya, T. Yamanaka, S. Morita, K. Fujitani, Y. Akamaru, K. Shimada, H. Hosaka, N. Nakayama, Y. Miyashita, T. Tsujinaka, J. Sakamoto

Annals of Oncology. 2018;29:viii228

Link1 Link2 Link3

SO13Pï¿½META-ANALYSIS OF IRINOTECAN MOLECULAR TARGETED SECOND LINE CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER

J. M. Weekes, Y.-H. Ho, S. Sabesan

ANZ Journal of Surgery. 2009;79:A82-A82

Link1 Link2

POSA168 Meta-Analysis and Cost-Effectiveness Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy for the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

X Zhang, W Su, Z Lin, Y Jian, J Xuan

Value in Health. 2022;25(1):S66-S67

Link1 Link2

POSC167 A Meta-Analysis and Cost-Minimization Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy with Targeted Molecular Agents in the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

X Zhang, W Su, Z Lin, T Bao, Y Jian, J Xuan

Value in Health. 2022;25(1):S120

Link1 Link2

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

Motoki Yoshida, Narikazu Boku, Atsushi Ohtsu, Manabu Muto, Fumio Nagashima, Shigeaki Yoshida

Gastric Cancer. 2001;4(3):144-149

Link1

Link2 Link3

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial

Kazuhiro Nishikawa, Kazumasa Fujitani, Hitoshi Inagaki, Yusuke Akamaru, Shinya Tokunaga, Masakazu Takagi, Shigeyuki Tamura, Naotoshi Sugimoto, Tadashi Shigematsu, Takaki Yoshikawa, Tohru Ishiguro, Masato Nakamura, Satoshi Morita, Yumi Miyashita, Akira Tsuburaya, Junichi Sakamoto, Toshimasa Tsujinaka

European Journal of Cancer. 2015;51(7):808-816

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.